Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06065059 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
A Phase 1 study, sponsored by Tango Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT06065059: Clinical Trial Phase 1 study, sponsored by Tango Therapeutics.
NCT06065059 is a Phase 1 study that was terminated before completion, run by Tango Therapeutics. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06065059, a Phase 1 study, was terminated before completion, sponsored by Tango Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors. The main question\[s\] it aims to answer are: * to evaluate the safety and tolerability of single agent and combination therapy * to determine the recommended dose for Phase 2 of single agent and combination therapy * to determine the pharmacokinetics of TNG348 as a single agent and in combination therapy * to evaluate the initial antineoplastic activity as a single agent and in combination therapy Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.
Primary Outcome
• To determine the MTD, RP2D(s), and dosing schedule of TNG348 single agent and in combination with olaparib
Interventions
- DRUG Olaparib
- DRUG TNG348
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-12-08 |
| Est. Completion | 2024-05-22 |
| Phase | Phase 1 |
Why NCT06065059 stopped before completion
NCT06065059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Olaparib is the first listed.
NCT06065059 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06065059 about?
NCT06065059 is a clinical study titled "Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors". The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors. The main question\[s\] it aims to answer are: * to evaluate the safety and toler...
What is the current status of trial NCT06065059?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2023-12-08. Estimated completion is 2024-05-22.
What interventions are being tested in trial NCT06065059?
The interventions under investigation include: Olaparib (DRUG), TNG348 (DRUG).
Who is sponsoring clinical trial NCT06065059?
This trial is sponsored by Tango Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06065059's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI